{"id":"NCT02481947","sponsor":"Braintree Laboratories","briefTitle":"A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults","officialTitle":"A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-05","primaryCompletion":"2015-11","completion":"2015-11","firstPosted":"2015-06-25","resultsPosted":"2020-06-25","lastUpdate":"2020-07-27"},"enrollment":459,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Idiopathic Constipation"],"interventions":[{"type":"DRUG","name":"BLI400 Laxative","otherNames":[]},{"type":"DRUG","name":"Lubiprostone","otherNames":[]}],"arms":[{"label":"BLI400 Laxative","type":"EXPERIMENTAL"},{"label":"Lubiprostone","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate a daily dose of BLI400 Laxative for safety and efficacy versus lubiprostone in constipated adults.","primaryOutcome":{"measure":"Complete Spontaneous Bowel Movement (CSBM) Response","timeFrame":"12 weeks","effectByArm":[{"arm":"BLI400 Laxative","deltaMin":47,"sd":null},{"arm":"Lubiprostone","deltaMin":56,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.016"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":15},"locations":{"siteCount":50,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":225},"commonTop":["diarrhea","flatulence"]}}